Latest Capital Raises News

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.

Livium Ltd has turned a profit in the first half of FY26 despite lower revenues, supported by cost cuts and a new joint venture. The company also secured $4.5 million in fresh capital to expand its lithium-ion battery recycling and rare earth initiatives.

Adherium Limited has raised $6.7 million through a Placement and Institutional Entitlement Offer, positioning itself to expand its digital respiratory management solutions and advance value-based care contracts with US insurers.

Austral Resources Australia has voluntarily suspended its shares on the ASX to complete a significant placement and secure a strategic investor commitment, with strong demand reported.

OzAurum Resources has kicked off a diamond drilling program at its Mulgabbie North Gold Project to advance heap leach feasibility and open pit design, supported by recent capital raising and ongoing plant refurbishment.

Marimaca Copper Corp. has launched a significant C$409 million global offering, combining treasury and secondary share sales, to fund key development and exploration activities at its flagship Chilean copper project.

Australian Bond Exchange Holdings Limited (ABE) has had its trading suspension lifted immediately following a capital raising announcement, signaling renewed investor engagement.

QEM Limited has raised $1.442 million through a well-supported placement to fund a strategic review of its flagship Julia Creek Vanadium and Energy Project and explore new critical minerals opportunities.

Identitii Limited faces a setback as Beauvais Capital terminates its underwriting agreement following Takeovers Panel orders, triggering shareholder withdrawal rights and uncertainty over the company’s capital raising plans.

Dexus has reported a strong half-year result with a $348.5 million profit turnaround, robust leasing growth, and strategic capital moves including a $950 million equity raise and a 10% on-market buyback.

INOVIQ Limited reported a $3.96 million net loss for H1 2026, driven by increased R&D spend, while securing $10.2 million to accelerate its exosome-based cancer diagnostics and therapeutics pipeline.

5E Advanced Materials reports Q2 FY2026 results with increased mineral resources and key shipments, while navigating ongoing funding uncertainties.